The DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index.
Current and future treatments for Alzheimer's disease
Open accessAbstract
Alzheimer's dementia (AD) is increasingly being recognized as one of the most important medical and social problems in older people in industrialized and non-industrialized nations. To date, only symptomatic treatments exist for this disease, all trying to counterbalance the neurotransmitter disturbance. Three cholinesterase inhibitors (CIs) are currently available and have been approved for the treatment of mild to moderate AD. A further therapeutic option available for moderate to severe AD is memantine, an N-methyl-D-aspartate receptor noncompetitive antagonist. Treatments capable of stopping or at least effectively modifying the course of AD, referred to as 'disease-modifying' drugs, are still under extensive research. To block the progression of the disease they have to interfere with the pathogenic steps responsible for the clinical symptoms, including the deposition of extracellular amyloid β plaques and intracellular neurofibrillary tangle formation, inflammation, oxidative damage, iron deregulation and cholesterol metabolism. In this review we discuss current symptomatic treatments and new potential disease-modifying therapies for AD that are currently being studied in phase I-III trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“After the sequential breakdown of the big precursor protein amyloid precursor protein (APP) by the β- and γ-e -secretase, Aβ peptides with A38, A40, and A42 being the most prevalent forms are generated (Yiannopoulou et al., 2013).”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Yiannopoulou et al., 2013
In the citing paper
“Memantine is known to be a non-competitive NMDA receptor antagonist that counteracts the negative effects of high glutamate concentrations in the brain (Yiannopoulou et al., 2013).”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Yiannopoulou et al., 2013
In the citing paper
“The most efficient and prospective class is passive Ab immunotherapy using mAbs. The chief disadvantages of this class of medicines are cerebral microhemorrhages and vasogenic edema (Yiannopoulou et al., 2013).”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Yiannopoulou et al., 2013
In the citing paper
“Memantine is a noncompetitive low-affinity NMDA-receptor open-channel blocker and affects glutamatergic transmission.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“AChEIs attempt at reducing the breakdown of acetylcholine levels in the brain of the patients with AD by inhibiting the responsible enzyme acetylcholinesterase in the synaptic cleft.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“According to the “amyloid hypothesis” Aβ production in the brain initiates a cascade of events leading to the clinical syndrome of AD.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“The basic pathophysiology and neuropathology of AD that drives the current research suggests that the primary histopathologic lesions of AD are the extracellular amyloid plaques and the intracellular Tau neurofibrillary tangles (NFTs).5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“The elements of the cascade include local inflammation, oxidation, excitoxicity (excessive glutamate), and tau hyperphosphorylation.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“The acetylocholinesterase inhibitors (AChEIs) which are approved for the treatment of AD are donepezil, galantamine, and rivastigmine.4,5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“It is the forming of amyloid oligomers to which neurotoxicity is mainly attributed and initiates the amyloid cascade.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Progressive neuronal destruction leads to shortage and imbalance between various neurotransmitters (eg, acetylcholine, dopamine, serotonin) and to the cognitive deficiencies seen in AD.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“A further therapeutic agent approved for moderate to severe AD is the low-to-moderate affinity, noncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist memantine.4,5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“The APP cleavage by α-secretase leads to nonamyloidogenic pathway, whereas APP cleavage by β-secretase (BACE1) leads to amyloidogenic pathway.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“The Aβ derives from a protein overexpressed in AD, APP through sequential proteolysis by β-secretase (BACE1) in the extracellular domain and γ-secretase in the transmembrane region.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Sequential cleavage of APP by BACE1 in the extracellular and γ-secretase in the transmembrane area results in the Aβ production.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“The crucial step in AD pathogenesis is the production of amyloid (Aβ), which forms SPs (insoluble and proteolysis-resistant fibrils).”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Aβ40 is somewhat aggregation-prone and it is mostly found in the cerebral vasculature as a main component of “cerebral amyloid angiopathy.””
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Oligomers can form Aβ-fibrils that will eventually form amyloid plaques.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Major sites of γ-secretase cleavage usually occur in positions 40 and 42 of Aβ, thus Aβ40 and Aβ42 oligomers are the main products of the sequential APP cleavage, as the amyloidogenic pathway is favored in neurons because of the greater plentifulness of BACE1.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Aβ40 usually constitutes more than 50% of total detected Aβ.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Unluckily, concerning γ-secretase, in addition to APP, this particular enzyme acts on many other substances and cleaves different transmembrane proteins. Notch receptor 1, which is essential for control of normal cell differentiation and communication, is among them.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Aβ42 is the most aggregation-prone form and has the tendency to cluster into oligomers.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Aβ38 is soluble, present in the vasculature of patients with sporadic and familial AD.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“On the contrary, the nonamyloidogenic processing is more favored in other cells without BACE1 predominance.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Cerebral microhemorrhages and vasogenic edema are the main drawbacks in this group of agents.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Abnormal accumulation or dyshomeostasis of metal ions such as iron, copper, and zinc has been associated with the pathophysiology of AD.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M. J., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K. S., Hasegawa, K., Hendrie, H. C., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,336
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869
Statins and the risk of dementia
Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S. S., & Drachman, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03155-x · Cited by 1,764
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
Clinical trial of indomethacin in Alzheimer's disease
Rogers, J., Kirby, L., Hempelman, S. R., Berry, D. A., McGeer, P. L., Kaszniak, A. W., Zalinski, J., Cofield, M., Mansukhani, L., Willson, P., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1609 · Cited by 991
Research works printed but not linked: 6
- Alva G., 2008, Psychiatry (Edgmont), 5, 27
- Ballard C., 2010, CNS Drugs, 24, 729
- Cummings J., 2008, Primary Psychiatry, 15, 66
- Hansen R., 2008, Clin Interv Aging, 3, 211
- Hey J., Koelsch G., Bilcer G., Jacobs A., Tolar M., Tang J. (2008) Single dose administration of the b-secretase inhibitor CTS21166 (ASP1720) reduces plasma Aβ40 in human subjects. Presented by Dr Koelsch in the International Conference on Alzheimer’s Disease (ICAD), Chicago, IL, USA, 26–31 July 2008. Available at: http://www.alzforum.org/new/detail.asp?id=1790
- Yiannopoulou K., 2009, Primary Psychiatry, 16, 29
Cited by
Sorted by citations
Items 501–600 of 682
Recent Advances in Computational Modeling of Multi-targeting Inhibitors as Anti-Alzheimer Agents
Thai, K., Tran, T., Tran, T., Cao, T., Ho, H. N., Huynh, P., Mai, T. T., Tran, T., Le, M.-T., & Tran, V.-T. (2023) · Neuromethods · doi:10.1007/978-1-0716-3311-3_8 · Cited by 2
Synthesis and neuroprotective activity of 3‐aryl‐3‐azetidinyl acetic acid methyl ester derivatives
Šachlevičiūtė, U., Gonzalez, G., Kvasnicová, M., Štěpánková, Š., Kleizienė, N., Bieliauskas, A., Zatloukal, M., Strnad, M., Sløk, F. A., Kvasnica, M., et al. (2023) · Archiv der Pharmazie · doi:10.1002/ardp.202300378 · Cited by 2
An Ensemble Classification Model to Predict Alzheimer’s Incidence as Multiple Classes
Raju, P. R., & Ananda Rao, A. (2024) · International Research Journal of Multidisciplinary Technovation · doi:10.54392/irjmt24314 · Cited by 2
Adeyemo, S. A., Ajao, M. Y., Ogundeyi, K. J., Femi-Akinlosotu, O., & Bakre, A. G. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118731 · Cited by 2
Novel Therapeutic Approaches in Alzheimer's Disease
Ingle, P. V., Lee, Y. L., Wong, X. Y., Tan, S. P., Lim, E. J., Chin, M. Y., Zhen, M. C. S., Safian, N. H. B., & Hatware, K. V. (2024) · Current Drug Therapy · doi:10.2174/0115748855332142240830114503 · Cited by 2
Bhattacharya, K., Sungoh, D., Kharmujai, D., Islam, A. F. M. M., Das, D., Jha, S. K., Chanu, N. R., Kashyap, B., Bora, N. S., Sahariah, B. J., et al. (2024) · Current Alzheimer Research · doi:10.2174/0115672050358848241211080546 · Cited by 2
Role of Galangin for the Treatment of Alzheimer’s Disease: Journey So Far and Road Ahead
Sharma, P., Sharma, T., Bashir, B., andotra, N., Awasthi, A., Patel, P. V., Subramaniyan, V., Chellappan, D. K., Gupta, G., Vishwas, S., et al. (2025) · Current Nutrition Reports · doi:10.1007/s13668-025-00669-6 · Cited by 2
Inhibitors of Tau-Phosphorylating Kinases
Fallacara, A. L., Trist, I. M. L., Schenone, S., & Botta, M. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2016_17 · Cited by 2
Alzheimer Disease diagnosis using Machine Learning Strategies
Stalin, G., Kurasakutla, S., Palli, J., & Gnana, M. (2020) · International Journal of Computer Applications · doi:10.5120/ijca2020920042 · Cited by 2
A Survey on Alzheimer’s Disease Detection and Classification
Mane, D., Patel, M. M., Sawant, M., Maiyani, K., & Patil, D. (2021) · Lecture notes in networks and systems · doi:10.1007/978-981-16-2641-8_60 · Cited by 2
Current drug treatments in Alzheimer’s disease
Pan, R. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v36i.6274 · Cited by 2
Crnich, E., Sanchez, E., Havens, M. A., & Kissel, D. S. (2023) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-023-02013-1 · Cited by 2
Exploring the Therapeutic Potential of Alkaloids in Alzheimer's Disease Management
Singh, R., Rani, N., Kaur, R., Chahal, G., Kumar, P., & Kaur, G. (2024) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/0118715249269092231109181638 · Cited by 2
Navigating the Landscape of Alzheimer's Disease: From Epidemiology to Drug Re-purposing
Rathi, K., Bhole, R. P., Bansode, P., & Motghare, N. (2024) · Advances in Pharmacology and Pharmacy · doi:10.13189/app.2024.120206 · Cited by 2
Bera, I. (2018) · Current Signal Transduction Therapy · doi:10.2174/1574362413666180312125419 · Cited by 2
Pharmacological Evaluation of Gentiana Kurroo Plant Extracts Against Alzheimer’s Disease
Ganai, B. A. (2019) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2019.14.002620 · Cited by 2
Betaine Induced Autophagy to Protect Neurons Against Amyloid Beta in Alzheimer’s DiseasePreprint
Meng, Q., Chen, Y., Chen, Y., Wang, L., & Zhao, L. (2021) · Research Square · doi:10.21203/rs.3.rs-199905/v1 · Cited by 3
Chaudhari, K. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820593-8.00016-1 · Cited by 1
GERIATRIC PATIENT MANAGEMENT IN THE EMERGENCY DEPARTMENT: CHALLENGES AND SOLUTIONS
Aslan, N., Yürümez, Y., & Durmuş, E. (2023) · International Target Medicine Journal · doi:10.29228/targetmedj.68221 · Cited by 1
Srivastava, V., Pattanayak, C., Sarkar, S., Das, M. C., & Chaudhury, H. C. (2024) · Asian Journal of Pharmaceutical Research and Health Care · doi:10.4103/ajprhc.ajprhc_144_24 · Cited by 1
Current Drugs Used: Classification and Pharmacology
Swain, S. S., Mude, L., Roychowdhury, P., Karri, V. V. S. R., Kuppusamy, G., Gobinath, M., & Subramaniyan, V. (2024) · Springer eBooks · doi:10.1007/978-981-96-0259-9_8 · Cited by 1
Rifat, M. M. H., Parvin, M. N., & Hossain, M. L. (2025) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20250302 · Cited by 1
Peyvand, P., Allami, P., & Rezaei, N. (2025) · Reviews in the Neurosciences · doi:10.1515/revneuro-2025-0025 · Cited by 1
Kavey, M. R. H., Hossain, M. A., Shohag, M. S. R., Ansari, I. A., Ansari, S. A., Alkahtani, H. M., Hossain, A., & Rahman, M. H. (2025) · In Silico Pharmacology · doi:10.1007/s40203-025-00434-1 · Cited by 2
Rao, D. M., Biswas, S. K., & Bordoloi, M. (2025) · Archives of Computational Methods in Engineering · doi:10.1007/s11831-025-10440-3 · Cited by 2
Understanding Brain Aging and Cognitive Decline
Kumar, D., Goel, F., Singh, P., Nand, S., & Prasanth, T. (2025) · Nutritional neurosciences · doi:10.1007/978-981-95-2790-8_1 · Cited by 1
Rodrigues, K. D. C., Oliveira, M. D. C., de Souza, I. C., Igansi, A. W., Lopes, A. V. B., Pacheco, C. O., Haas, S. E., Schumacher, R. F., & Luchese, C. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06967-9 · Cited by 2
Tripathi, P., & Shah, J. (2026) · Neurochemical Research · doi:10.1007/s11064-026-04721-x · Cited by 1
Zhu, S., Li, Y., Lin, C., Liu, X., Luo, Y., Qian, H., & Tang, Z. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05225-9 · Cited by 1
Rahman, M., Akter, K., Rani, A., Park, M. N., & Kim, B. (2026) · Nutrients · doi:10.3390/nu18111796 · Cited by 2
Phullay, P., Panwar, R., Bajwa, S., Wadhwa, K., Chauhan, P., Pahwa, R., Kriplani, P., Rajak, H., Awasthi, R., & Dureja, H. (2026) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-026-00616-z · Cited by 1
Deepika, D., Kumar, J., Ali, S. A., Namdeo, A. G., & Flora, S. J. S. (2026) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2026.127929 · Cited by 1
Badakhshan, M., Mirzaei, S. M. M., Salehinia, H., Talebi, S. F., Nakhaee, S., & Avan, R. (2026) · Pharmaceutical Sciences · doi:10.34172/ps.026.42850 · Cited by 1
Negi, M., Phatale, V., Amulya, E., Vambhurkar, G. B., Kumar, R., & Srivastava, S. (2026) · BioNanoScience · doi:10.1007/s12668-026-02777-1 · Cited by 1
Small Molecule-Assisted PET: Approaches to Imaging of Conformational Diseases of the Brain
Pissarek, M. (2017) · World Journal of Neuroscience · doi:10.4236/wjns.2017.71010 · Cited by 1
Chakraborty, S., & Basu, S. (2017) · Springer eBooks · doi:10.1007/978-981-10-3162-5_9 · Cited by 1
Risk Factors and Clinical Treatments of Alzheimer’s Disease
Hao, J. (2019) · Journal of Physics Conference Series · doi:10.1088/1742-6596/1168/3/032120 · Cited by 1
Kinetics of human butyrylcholinesterase inhibition by 1,9-dimethyl-methylene blue
Biberoğlu, K. (2021) · Journal of the Turkish Chemical Society Section A Chemistry · doi:10.18596/jotcsa.853598 · Cited by 1
Sabancı, N. (2021) · Erzincan Üniversitesi Fen Bilimleri Enstitüsü Dergisi · doi:10.18185/erzifbed.856269 · Cited by 1
Krisandi, G., Siagian, R. M., Karina, K., & Rosadi, I. (2021) · Journal of Skin and Stem Cell · doi:10.5812/jssc.109466 · Cited by 1
Javed, H., & Ojha, S. K. (2022) · Springer eBooks · doi:10.1007/978-981-16-7606-2_20 · Cited by 1
Reddy, G. V., Raju, B. S. M., Varshith, K., Sahil, S., & Vardhan, L. H. (2023) · E3S Web of Conferences · doi:10.1051/e3sconf/202339101047 · Cited by 1
Caracterização Geral das Demências Vasculares: O desafio e a importância do diagnóstico preciso
Piauilino, E. N., Ribeiro, R. M., Filho, C. A. A. D., Pereira, M. J. V., & Barros, V. D. J. C. (2023) · Seven Editora eBooks · doi:10.56238/medfocoexplconheci-012 · Cited by 1
Kamal, I. M., Das, A., Datta, S., Paul, K., Chakrabarti, S., Chakrabarti, S., & Bhattacharjee, P. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2248274 · Cited by 1
Targeting Mitochondrial Dynamics as a Restorative Approach in the Treatment of Alzheimer’s Disease
Pandey, R., Bisht, P., Kumari, A., Ray, A., Ravichandiran, V., & Kumar, N. (2023) · Springer eBooks · doi:10.1007/978-981-99-2657-2_9 · Cited by 1
Detection of Alzheimer’s Disease Using Convolutional Neural Network
Jovina, D. J., & Jayasree, T. (2023) · Algorithms for intelligent systems · doi:10.1007/978-981-99-5881-8_32 · Cited by 1
Lead Compounds for Brain Protection against Alzheimer’s
AlSalem, H., Al-Ghamdi, A. R., & Issa, I. S. (2023) · International Journal of Science and Research Archive · doi:10.30574/ijsra.2023.10.1.0214 · Cited by 1
Improving Alzheimer's Disease Diagnosis with Artificial Intelligence and Neuropsychological Tests
Raghuraman, A., & Avery, E. W. (2023) · Journal of Student Research · doi:10.47611/jsrhs.v12i3.4777 · Cited by 1
Alzheimer’s disease: Systematic review of recent substantial therapeutic targets
Sharma, N., & Aulakh, M. K. (2024) · AIP conference proceedings · doi:10.1063/5.0192462 · Cited by 1
The evolution of Alzheimer’s disease therapies: A comprehensive review
Paul, P., Bhattacharjee, A., Bordoloi, S. K., & Paul, U. K. (2024) · Annals of Medical Science and Research · doi:10.4103/amsr.amsr_37_23 · Cited by 1
Thakkar, A. P., Vora, A., Kaur, G., Akhtar, J., & Kumar, P. (2024) · Journal of Planar Chromatography – Modern TLC · doi:10.1007/s00764-024-00290-3 · Cited by 1
Current Therapeutic Options and Repurposed Drugs for Neurodegeneration
Dhaneshwar, S. S., Bhat, M. A., Singh, A., & Roy, S. (2024) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815238754124010012 · Cited by 1
Update on the pharmacological management of neurodegenerative diseases: Alzheimer’s disease
Flepisi, B. T., Hanser, S., & Balmith, M. (2024) · SA pharmaceutical journal. · doi:10.36303/sapj.0492 · Cited by 1
Current Perspectives of Nanotherapeutics for the Treatment of Alzheimer’s Disease
Mishra, S., Senthilkumar, D., & Yadav, V. K. (2024) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815256505124010010 · Cited by 1
Bains, R. S., Peracha, H. T., Chandrasekaran, S. H., Reddy, K. S., Kumar, D. V., Prakash, A., Singh, M., Khan, M. K., & Rath, S. (2025) · Cureus · doi:10.7759/cureus.84885 · Cited by 1
Nelson, D. W., Scire, G. M., Cheung, C. H., Varude, V. R., Quinones, G. B., Bentley, M., Zha, R. H., & Gilbert, R. J. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107119 · Cited by 1
Safety and effectiveness of Donepezil and Memantine in Alzheimer's Disease
Ghosh, A. (2025) · International Journal of Pharmaceutical Sciences and Drug Research · doi:10.25004/ijpsdr.2025.170310
Chettupalli, A. K., Gupta, N., Bukke, S. P. N., Singh, M. P., & Mandal, C. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118803 · Cited by 1
Alzheimer's Disease and Current Approaches in its Treatment: Review
SOYLU, Ö., & Karalı, N. (2017) · Turkiye Klinikleri Journal of Pharmacy Sciences · doi:10.5336/pharmsci.2017-55739 · Cited by 1
Kabel, A. M., Borg, H. M., Elmaaboud, M. A. A., & Ashour, A. M. (2019) · Bulletin of Egyptian Society for Physiological Sciences · doi:10.21608/besps.2019.11331.1018 · Cited by 1
Lee, M. J. (2019) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2019.169 · Cited by 1
An Alternate View of Neuroprotection with Peptides in Alzheimer’s Disease
King, S. P., & Suphioglu, C. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.91065 · Cited by 1
Yang, D., Huang, R., Qing, K., & Hong, K. (2020) · International Conference on Control, Automation and Systems (ICCAS) · doi:10.23919/iccas50221.2020.9268361 · Cited by 1
Using big data methods to understand Alzheimer’s disease
Warren, S. L., Moustafa, A. A., & Alashwal, H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821334-6.00004-1 · Cited by 1
Beneficial Effects of Citrus Flavonoids Against Aβ Pathology in Alzheimer’s Disease
Javed, H., Ojha, S. K., & Jamali, M. C. (2022) · Springer eBooks · doi:10.1007/978-981-16-7606-2_19 · Cited by 1
Reddy, K. S., Arjun, N. S., & Mudiraj, K. H. (2023) · International Journal on Recent and Innovation Trends in Computing and Communication · doi:10.17762/ijritcc.v11i7s.6993 · Cited by 1
Exenatide Stimulates Hippocampal Autophagic Activity in Alzeheimer Rat ModelPreprint
Abdo, E., Saad, M. A., Firgany, A. E. D., Mosaad, Y. M., & Eldusoky, S. (2020) · doi:10.22541/au.159103395.53489994
Pathak, K. P., Brooke, J. M., & Gaire, T. (2020) · doi:10.2196/preprints.26024 · Cited by 1
Foloppe, D. A. (2017) · theses.fr (ABES) · doi:10.70675/ea5c564azcf19z4d1dzacdezb265118ff3a8 · Cited by 1
Meðferðarúrræði við Alzheimerssjúkdómnum : lyf og lyfleysur
Árnadóttir, E. S. (2014)
Correlati neurobiologici nell'anziano con malattia di alzheimer e altre demenze
Guaita, A. (2013) · RICERCHE DI PSICOLOGIA · doi:10.3280/rip2012-002016
Psychopharmacologic Treatments for Alzheimer Disease and Related Dementias
Gomoll, B. P., Sanders, B., & Caserta, M. (2014) · Psychopharm Review · doi:10.1097/01.psyphr.0000442519.29442.6a · Cited by 1
Strategic options for the Pharmaceutical Industry in times of Challenge and Change
Pachidou, F. (2014) · Repository for Publications and Research Data (ETH Zurich) · doi:10.3929/ethz-a-010278917
Antyborzec, I. (2016) · Dublin City University Open Access Institutional Repository (Dublin City University)
Bergkvist, L. (2017) · Linköping studies in science and technology. Dissertations · doi:10.3384/diss.diva-137452
Assessment of Gut Microbiome Role in Diet-Related Changes in Cognition
Caballero-Ignacio, C. (2017)
ENCAPSULAMENTO DE RIVASTIGMINA EM NANOPARTÍCULAS POLIMÉRICAS PARA TRATAMENTO DE ALZHEIMER
Mangia, L. H. R., Ferraz, H. C., & PINTO, J. C. (2018) · Blucher Chemical Engineering Proceedings · doi:10.5151/cobeq2018-co.113
El polimorfismo humano ARG72PRO de Tp53 condiciona a la susceptibilidad neuronal a B-Amiloide
de Gauna, R. L. R. (2016) · Gredos (University of Salamanca) · doi:10.14201/gredos.132968
Amyloid aggregates: detection and interaction
Rahman, M. M. (2018) · Epsilon Open Archive (Sveriges lantbruksuniversitet biblioteket (Swedish University of Agricultural Sciences))
Modelling the neurobiology of Alzheimer’s disease in vitro
Muñoz, S. S. (2019) · Research Online (University of Wollongong)
Electromagnetic Field: A Potential Innovative Treatment for Alzheimer’s Disease
Ahmad, R. H. M. A., Fakhoury, M., & Lawand, N. (2020) · Current Psychiatry Research and Reviews · doi:10.2174/2666082216666200408103701
Wang, K. R., Jeong, W., Lo, A., & Zaidi, K. M. (2020) · Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · doi:10.26685/urncst.189
Revisiting Alzheimer’s Disease
Salwa, & Kumar, L. (2020) · Springer eBooks · doi:10.1007/978-981-15-5167-3_7
Deep Learning Architectures for Medical Diagnosis
Malik, V., & Maheswari, S. U. (2020) · Springer eBooks · doi:10.1007/978-3-030-41862-5_161
Ghazali, M. I. (2019) · UTHM Institutional Repository (Universiti Tun Hussein Onn Malaysia)
Inhibitory effects of novel benzamide derivatives towards acetylcholinesterase enzyme
Yamalı, C., Gul, H. I., Levent, S., & Demir, Y. (2021) · Journal of the Turkish Chemical Society Section A Chemistry · doi:10.18596/jotcsa.842465
FARELERDE SKOPOLAMİNLE BOZULMUŞ ÖĞRENME VE BELLEK ÜZERİNE NÖROTENSİN AGONİSTİ PD149163’ÜN ETKİSİ
Topuz, R. D., & Kaya, O. (2021) · İnönü Üniversitesi Sağlık Hizmetleri Meslek Yüksek Okulu Dergisi · doi:10.33715/inonusaglik.829609
Chen, C., Liu, Q., Moorakonda, R. B., Kandiah, N., Tan, B. Y., Villaraza, S. G., Cano, J., & Venketasubramanian, N. (2021) · Research Square · doi:10.21203/rs.3.rs-494674/v1
Tolentino, R., McMahon, A., & Coward, E. (2021) · Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · doi:10.26685/urncst.309
Cuidar el monte, cuidando el rebaño
Barasoain, R. (2005) · Fertilidad de la tierra: revista de agricultura ecológica
Search for early TTR-related biomarkers in a transgenic AD mouse model
Santos, L. M. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/h957-t073
Human Nervous System Disorders
(2019) · Advances in bioinformatics and biomedical engineering book series · doi:10.4018/978-1-5225-8066-9.ch018
Marine Drugs as a Valuable Source of Natural Biomarkers Used in the Treatment of Alzheimer’s Disease
U, U. N. U. D. U. N. (2022) · Open Access Journal of Biogeneric Science and Research · doi:10.46718/jbgsr.2022.10.000253
Wu, M. J., bin Chen, & Gao, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-1550199/v1
(2015) · European Pharmaceutical Journal · doi:10.1515/afpuc-2015-0022
Pandohee, J., & Mahomoodally, M. F. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819212-2.00015-3
Allinquant, B. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.729275349.793537672
Qian, H., Yu, C., Zhu, H., Ding, Q., Cai, Y., Jing, J., Xu, X. P., Guo, R., Zhang, H., Liu, H. S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1744060/v1
Metadata
- Authors
- Yiannopoulou, K. G., & Papageorgiou, S. G.
- Affiliations
- Laiko General Hospital of Athens (GR)
- National and Kapodistrian University of Athens (GR)
- Venue
- Therapeutic Advances in Neurological Disorders
- Publisher
- SAGE Publications
- Published
- 2012-10-15
- Volume
- 6
- Issue
- 1
- Pages
- 19-33
- ISSN
- 1756-2856 (ISSN-L)
- 1756-2864
- PMC
- PMC3526946
- OpenAlex
- W1987204546
- Cited by
- 677
- References
- 83
- Citations by year
- 2026: 35 · 2025: 55 · 2024: 66 · 2023: 70 · 2022: 84 · 2021: 81 · 2020: 83 · 2019: 61 · 2018: 45 · 2017: 37 · 2016: 27 · 2015: 9 · 2014: 9 · 2013: 14
- FWCI
- 6.86
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Therapeutic Advances in Neurological Disorders (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, cholinesterase inhibitors, memantine, disease-modifying therapy, symptomatic treatment, amyloid plaques, neurofibrillary tangles, oxidative stress, neuroinflammation, cholesterol metabolism, NMDA receptor antagonists, clinical trials
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
